PVLA
Palvella Therapeutics Inc

258
Mkt Cap
$1.54B
Volume
229,065.00
52W High
$151.18
52W Low
$18.23
PE Ratio
-8.91
PVLA Fundamentals
Price
$112.37
Prev Close
$117.61
Open
$118.11
50D MA
$104.97
Beta
1.05
Avg. Volume
435,761.84
EPS (Annual)
-$7.83
P/B
32.21
Rev/Employee
$0.00
$44.95
Loading...
Loading...
News
all
press releases
Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) Signal
Key PointsAn executive at Palvella Therapeutics reported selling 4,302 common shares for approximately $508,000 on March 18, 2026...
Nasdaq News: Markets·3d ago
News Placeholder
More News
News Placeholder
Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $270.00 at HC Wainwright
HC Wainwright increased their target price on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the stock a "buy" rating in a research report on Tuesday...
MarketBeat·4d ago
News Placeholder
Palvella Therapeutics (PVLA) to Release Earnings on Monday
Palvella Therapeutics (NASDAQ:PVLA) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-palvella-therapeutics-stock...
MarketBeat·5d ago
News Placeholder
Palvella Therapeutics (NASDAQ:PVLA) COO Sells $507,592.98 in Stock
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) COO Kathleen Goin sold 4,302 shares of the business's stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total value of $507,592.98. The sale was disclosed in a document...
MarketBeat·7d ago
News Placeholder
Kathleen Goin Sells 4,302 Shares of Palvella Therapeutics (NASDAQ:PVLA) Stock
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) COO Kathleen Goin sold 4,302 shares of the company's stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total value of $507,592.98. The transaction was disclosed in a...
MarketBeat·8d ago
News Placeholder
Fred Alger Management LLC Increases Stock Holdings in Palvella Therapeutics, Inc. $PVLA
Fred Alger Management LLC grew its stake in Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) by 1,279.1% during the third quarter, according to the company in its most recent disclosure with...
MarketBeat·11d ago
News Placeholder
Palvella Therapeutics (NASDAQ:PVLA) Earns Buy Rating from Chardan Capital
Chardan Capital reiterated a "buy" rating and issued a $210.00 price target on shares of Palvella Therapeutics in a report on Monday...
MarketBeat·12d ago
News Placeholder
First Light Asset Management LLC Buys New Holdings in Palvella Therapeutics, Inc. $PVLA
First Light Asset Management LLC purchased a new position in Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) during the 3rd quarter, according to the company in its most recent filing with...
MarketBeat·12d ago
News Placeholder
Apis Capital Advisors LLC Makes New Investment in Palvella Therapeutics, Inc. $PVLA
Apis Capital Advisors LLC bought a new stake in Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·13d ago
News Placeholder
Palvella Therapeutics (NASDAQ:PVLA) Shares Down 8.7% - Should You Sell?
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 8.7% - Time to Sell...
MarketBeat·15d ago
<
1
2
...
>

Latest PVLA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.